Here's What You May Have Missed About BridgeBio Pharma (BBIO)

By Naomi Wentworth • Tuesday, November 07 17:13 • Permanent Link

Shares of Small-cap health care company BridgeBio Pharma moved 5.4% this evening, and are now trading at $29.39 per share. The average analyst target price for the stock is $46.4.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.

Based on its trailing earning per share of -3.91, BridgeBio Pharma has a trailing 12 month Price to Earnings (P/E) ratio of -7.5 BBIO has a forward P/E ratio of -10.4 based on its earnings guidance of $None.

The company has a price to earnings growth (PEG) ratio of 0.12. A number between 0 and 1 could mean that the market is undervaluing BridgeBio Pharma's estimated growth potential

None

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.